1-Methyl-2-[1-[2-methyl-6-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]azetidin-3-yl]benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-Methyl-2-[1-[2-methyl-6-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]azetidin-3-yl]benzimidazole
• 英文别名: 1-methyl-2-[1-[2-methyl-6-(2-methylpyrrolidin-1-yl)pyrimidin-4-yl]azetidin-3-yl]benzimidazole
• 化学式: C₂₁H₂₆N₆
• 分子量: 362.5
• InChiKey: BYFHRYSEJHPFBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] AZETIDINE BENZIMIDAZOLES AS PDE10 INHIBITORS<br/>[FR] AZÉTIDINE BENZIMIDAZOLES UTILISABLES EN TANT QU'INHIBITEURS DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014078214A1

  公开（公告）日：2014-05-22

  The present invention is directed to substituted azetidine benzimidazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.